List of Excipients in Branded Drug INDERAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ANI Pharmaceuticals Inc	INDERAL	propranolol hydrochloride	62559-520	D&C RED NO. 28
ANI Pharmaceuticals Inc	INDERAL	propranolol hydrochloride	62559-520	DIETHYL PHTHALATE
ANI Pharmaceuticals Inc	INDERAL	propranolol hydrochloride	62559-520	ETHYLCELLULOSE
ANI Pharmaceuticals Inc	INDERAL	propranolol hydrochloride	62559-520	FD&C BLUE NO. 1
ANI Pharmaceuticals Inc	INDERAL	propranolol hydrochloride	62559-520	GELATIN

Inderal Excipient Strategy and Commercial Opportunities for Propranolol

Last updated: August 10, 2026

Inderal is the original branded propranolol product, with commercial value now concentrated in formulation differentiation rather than core active-ingredient exclusivity. The strongest opportunities are age-appropriate liquid products, improved extended-release delivery, alcohol- and sugar-free formulations, palatable pediatric products, and region-specific products that address excipient restrictions. Propranolol’s long clinical history, broad indications, low API cost, and generic competition make excipient selection central to product positioning, regulatory execution, and margin protection.

What is Inderal and which formulations are commercially relevant?

Inderal contains propranolol hydrochloride, a nonselective beta-adrenergic blocker. Original and generic products have been marketed in immediate-release tablets, extended-release capsules, and oral liquid formulations. Propranolol is used for hypertension, angina, arrhythmias, migraine prevention, hypertrophic subaortic stenosis, essential tremor, and other cardiovascular or neurologic conditions. Pediatric propranolol products are also used for infantile hemangioma, although the principal FDA-approved product for that indication is Hemangeol, not Inderal [1, 2].

Product type	Release profile	Primary commercial use	Excipient opportunity
Immediate-release tablet	Rapid release	Chronic cardiovascular and neurologic therapy	Low-cost, swallowability, dose flexibility
Extended-release capsule	Once-daily release	Hypertension and cardiovascular maintenance	Release control, capsule robustness, dose uniformity
Oral solution or suspension	Immediate release	Pediatric and dysphagia markets	Taste masking, preservative system, dosing accuracy
Orally disintegrating tablet	Rapid disintegration	Dysphagia and convenience markets	Taste masking, low friability, rapid dispersion
Multiparticulate capsule	Modified release	Pediatric or flexible-dose therapy	Sprinkleability and individualized dosing
Abuse-deterrent or tamper-resistant format	Modified administration properties	Limited strategic relevance	Generally weak opportunity for propranolol

The original Inderal brand does not provide a meaningful basis for premium pricing by itself. Commercial value depends on clinical convenience, tolerability, supply reliability, and evidence supporting a differentiated dosage form.

What excipients are used in propranolol products?

Inactive ingredients differ by manufacturer, strength, dosage form, and jurisdiction. FDA-approved labels and DailyMed records should be treated as the controlling sources for product-specific composition [3, 4].

Immediate-release tablets

Typical excipient functions include:

• Dilution and bulk: lactose, microcrystalline cellulose, or starch
• Disintegration: starch derivatives, croscarmellose sodium, or sodium starch glycolate
• Lubrication: magnesium stearate
• Glidancy: colloidal silicon dioxide
• Coating: hypromellose, polyethylene glycol, titanium dioxide, talc, or colorants
• Compression support: microcrystalline cellulose and selected starch systems

The main commercial issue is not technical feasibility. It is avoiding unnecessary excipient liabilities while maintaining tablet hardness, rapid dissolution, low friability, and acceptable stability.

Extended-release capsules

Extended-release propranolol products generally use multiparticulate or coated-particle technology. The release system can include polymer coatings based on ethylcellulose, methacrylate copolymers, or other rate-controlling materials. The capsule shell commonly uses gelatin or hypromellose, with colorants and opacifiers selected according to market requirements.

Key formulation variables are:

1. Particle-size distribution of drug-loaded pellets.
2. Coating weight gain and polymer permeability.
3. Dose uniformity across capsule filling.
4. Food-effect performance.
5. Stability of the coating during storage and shipping.

A reformulated extended-release product must demonstrate reliable release across pH conditions and clinically relevant food states. A simple excipient substitution can alter pharmacokinetics and may trigger a new bioequivalence program.

Oral liquids

Liquid propranolol products require tighter excipient controls because the API is susceptible to taste and dosing errors. Common functional categories include:

• Purified water as the vehicle
• Sweeteners such as sucrose, sorbitol, sucralose, or other polyols
• Buffering agents for pH control
• Preservatives for multidose products
• Flavor systems
• Suspending or viscosity-enhancing agents when a suspension is used
• Chelating or antioxidant components where justified by stability data

A liquid product intended for infants should minimize unnecessary excipients, avoid alcohol, and control osmolality and preservative exposure. Products containing sucrose may be unsuitable for certain patients or markets. Products containing sorbitol or other polyols require attention to gastrointestinal tolerance and pediatric dose volume.

What excipient strategy best fits a new Inderal-compatible product?

The strongest strategy is a platform approach rather than a single reformulation.

Strategy 1: Preservative-free unit-dose oral solution

A preservative-free solution in unit-dose containers could target pediatric hospitals, outpatient clinics, and patients with swallowing difficulties. The product would require robust microbiological controls through packaging and manufacturing design rather than reliance on a multidose preservative system.

Commercial advantages include:

• Lower preservative exposure
• Better pediatric positioning
• Reduced dosing ambiguity
• Potential use in institutional settings
• Improved portability and dispensing accuracy

The principal drawbacks are higher packaging costs, greater fill-finish complexity, and potentially shorter in-use flexibility.

Strategy 2: Sugar-free, alcohol-free flavored solution

A sugar-free solution would address dental, metabolic, and institutional concerns. The formulation should use a low-volume dose, a stable preservative system if multidose packaging is retained, and a flavor profile capable of masking propranolol’s bitterness.

Taste masking should be tested through human sensory evaluation, not only electronic taste measurements. Propranolol’s bitterness can be addressed through sweetener combinations, flavor layering, viscosity control, and, where technically justified, ion-pairing or microencapsulation.

Strategy 3: Pediatric multiparticulate product

A sprinkle capsule or sachet containing taste-masked immediate-release microparticles could provide dose flexibility without requiring a liquid. This format is attractive for patients who cannot swallow tablets but can take particles mixed with soft food.

Critical specifications include:

• No chewing requirement
• Minimal drug release in the mouth
• Uniform distribution after sprinkling
• Compatibility with approved food vehicles
• Stable dose delivery at partial capsule use
• Clear caregiver instructions

This approach could produce stronger differentiation than another conventional tablet, but it requires careful food compatibility and dose-recovery studies.

Strategy 4: Improved once-daily extended-release product

A new extended-release product could target adherence and smoother plasma exposure. The opportunity is commercially credible only if the formulation shows a meaningful advantage in dosing convenience, tolerability, food-effect control, or adherence.

Possible technologies include coated pellets, matrix tablets, osmotic systems, and polymer-lipid matrices. For propranolol, multiparticulate delivery may offer better control of dose dumping and more flexible capsule manufacture than a single high-load matrix.

What formulation patents could protect a new propranolol product?

The active ingredient is long off-patent, so protection would need to focus on formulation and manufacturing claims. Potential claim categories include:

Claim category	Potential scope	Commercial value
Taste-masked particles	Polymer-coated or ionically complexed propranolol particles	High for pediatric products
Extended-release system	Defined dissolution profile and polymer architecture	High if clinically differentiated
Low-dose-volume liquid	Concentrated solution with stability and taste profile	Moderate to high
Preservative-free packaging	Unit-dose container and microbiological control system	Moderate
Sprinkle formulation	Particle size, coating, food compatibility, and release profile	High
Manufacturing process	Coating, drying, blending, or capsule-filling parameters	Moderate
Combination excipient system	Specific sweetener, buffer, preservative, and flavor ranges	Usually narrow

Formulation patent strength depends on more than claiming excipients by name. Stronger claims link composition to measurable performance, such as dissolution, stability, taste masking, dose uniformity, or pharmacokinetic behavior. Claims limited to a routine substitution of lactose, mannitol, or a standard lubricant are more vulnerable to obviousness challenges.

When does Inderal lose exclusivity and what is the Orange Book status?

Inderal’s original active-ingredient and product exclusivity periods have expired. Propranolol hydrochloride is available through multiple generic manufacturers, and FDA-listed products include immediate-release tablets and extended-release dosage forms [5].

Exclusivity issue	Current commercial implication
Original propranolol compound patent	Expired
Original Inderal product exclusivity	Expired
Immediate-release generic entry	Established
Extended-release generic entry	Established, subject to product-specific approvals
New formulation exclusivity	Possible only for a newly approved product
Pediatric exclusivity	Depends on a specific FDA grant and product program
Orphan exclusivity	Not applicable to standard Inderal indications

A new propranolol formulation could potentially receive three years of FDA marketing exclusivity for a qualifying new clinical investigation supporting approval of a change, modification, or new indication under Section 505(b)(2). That exclusivity would not block all propranolol products. It would generally be limited to the approved conditions of use or the protected formulation change.

The Orange Book status must be assessed by product and application number. The presence of an Orange Book listing for a proprietary formulation does not create exclusivity for the propranolol molecule as a whole [5].

Which companies are challenging Inderal and propranolol products?

The competitive threat comes primarily from generic manufacturers rather than biosimilar developers. Propranolol is a small molecule, so biosimilar pathways do not apply.

Competition includes:

• Generic immediate-release tablet manufacturers
• Extended-release capsule manufacturers
• Compounding pharmacies offering extemporaneous liquids
• Hospital and specialty distributors
• Branded pediatric propranolol products
• New drug applications using 505(b)(2) formulation strategies

Paragraph IV litigation is generally relevant only when a listed patent remains active for a particular extended-release, liquid, or other proprietary formulation. The expired status of the original Inderal technology means a new applicant would need to monitor patents attached to later products rather than rely on legacy Inderal protection. Product-specific FDA Orange Book records and the FDA Paragraph IV database are the relevant sources for live challenges [5, 6].

What patent litigation and settlement risks affect a new formulation?

A new propranolol product faces four principal IP risks:

1. Coating and multiparticulate patents. Broad claims covering coated propranolol particles could affect pellet-based products.
2. Taste-masking patents. Pediatric products may encounter claims covering polymer barriers, ion-exchange resins, or specific flavor systems.
3. Dissolution-profile patents. A formulation could fall within claims defined by release windows rather than ingredient identity.
4. Manufacturing patents. Commercial coating and drying processes may be protected even where composition claims are weak.

A freedom-to-operate review should separate expired Inderal patents from later patents covering proprietary delivery systems. A design-around program should prioritize independent control of particle size, coating chemistry, release profile, and packaging.

What FDA regulatory pathway applies to an improved Inderal product?

The regulatory pathway depends on the proposed product.

Product concept	Likely pathway
Conventional immediate-release tablet equivalent	ANDA
Conventional extended-release equivalent	ANDA, with product-specific bioequivalence requirements
Novel liquid with a new clinical benefit	505(b)(2)
New pediatric formulation with supporting clinical data	505(b)(2) or ANDA, depending on equivalence
New indication or clinically meaningful delivery change	505(b)(2)
Compounded formulation	State and federal compounding framework, not a conventional commercial approval

FDA review will focus on inactive-ingredient safety, dissolution, bioequivalence, stability, container closure, dosing-device accuracy, and labeling. Pediatric products receive particular scrutiny for dose measurement, excipient exposure, palatability, and administration instructions. FDA’s Inactive Ingredient Database can support excipient precedent analysis, but prior use in another product does not automatically establish suitability for a new route, dose, age group, or concentration [7].

How strong is the commercial opportunity for an excipient-led Inderal product?

The opportunity is strongest where excipients solve a documented use problem.

Opportunity	Market attractiveness	Technical risk	IP potential
Low-cost generic tablet	Low	Low	Low
Sugar-free liquid	Moderate	Moderate	Moderate
Preservative-free unit dose	Moderate to high	Moderate	Moderate
Pediatric taste-masked multiparticulates	High	High	High
New once-daily extended release	Moderate to high	High	High
Orally disintegrating tablet	Moderate	Moderate	Moderate
Hospital-ready concentrated solution	Moderate	Moderate	Moderate

Revenue exposure is greatest in chronic cardiovascular therapy, but price competition is severe. Pediatric and specialty formulations can support higher gross margins because caregivers and institutions value dosing precision, palatability, and supply continuity. The commercial ceiling remains constrained by the availability of low-cost tablets and the clinical familiarity of generic propranolol.

What geographic markets offer the best formulation opportunities?

The United States offers the clearest pathway for a differentiated product through an ANDA or 505(b)(2) application, but competition is mature. Europe and other regulated markets may offer opportunities for pediatric formulations, provided excipient restrictions and local labeling requirements are addressed.

Key geographic considerations include:

• EU restrictions and market sensitivity regarding certain colorants and preservatives
• Pediatric excipient guidance from European regulators
• Different availability of oral liquids and compounded products
• Local requirements for measuring devices
• Country-specific patent and supplementary protection certificate records
• National reimbursement treatment for branded reformulations

A global product should use an excipient platform that can be adapted without changing the core dosage form. Sugar-free, alcohol-free, low-colorant designs generally provide broader geographic flexibility.

Key Takeaways

• Inderal and propranolol are off-patent, so commercial differentiation must come from dosage form, excipient design, manufacturing, or clinical positioning.
• The highest-value opportunity is a palatable, low-volume pediatric formulation with strong dose accuracy.
• Preservative-free unit-dose liquids and sprinkleable taste-masked multiparticulates offer credible differentiation.
• Extended-release reformulation has value only if it improves adherence, food-effect control, pharmacokinetics, or tolerability.
• Formulation patents should claim measurable performance, not only routine excipient substitutions.
• Propranolol is a small molecule and has no biosimilar pathway.
• FDA Orange Book analysis must be performed by product and application because legacy Inderal exclusivity has expired.
• A 505(b)(2) strategy may provide limited regulatory exclusivity for a clinically supported new formulation.
• The best commercial target is a specialty product that solves administration and tolerability problems rather than another conventional tablet.

FAQs About Inderal Excipient and Formulation Opportunities

Can propranolol be reformulated as an orally disintegrating tablet?

Yes. An orally disintegrating propranolol tablet could target dysphagia and convenience markets, but taste masking is essential because propranolol is bitter. The product would require rapid disintegration, acceptable mouthfeel, low friability, and bioequivalence support.

Is lactose-free Inderal commercially attractive?

Potentially. A lactose-free tablet could address excipient preferences and intolerance concerns, but lactose-free status alone is unlikely to support durable premium pricing. The opportunity is stronger when combined with improved swallowability, lower tablet weight, or a differentiated patient segment.

Can a propranolol liquid receive new FDA exclusivity?

A qualifying new liquid may be eligible for limited exclusivity if approval relies on new clinical investigations under the 505(b)(2) pathway. The exclusivity would depend on the approved formulation or indication and would not restore exclusivity for propranolol generally.

What is the main technical barrier for pediatric propranolol products?

Taste masking is the principal barrier, followed by dose uniformity, stability, excipient safety, and accurate administration. A product must prevent unacceptable bitterness without delaying release or creating unreliable dosing when mixed with food.

Are compounded propranolol liquids a major commercial threat?

They can be, particularly for pediatric and dysphagia patients. An approved commercial product can compete through standardized concentration, validated stability, dosing devices, supply consistency, and lower preparation burden for pharmacies and hospitals.

References

1. U.S. Food and Drug Administration. (2016). Inderal LA: Propranolol hydrochloride extended-release capsules prescribing information.
2. U.S. Food and Drug Administration. (2023). Hemangeol: Propranolol hydrochloride oral solution prescribing information.
3. National Library of Medicine. (2024). DailyMed: Propranolol hydrochloride tablet labels.
4. National Library of Medicine. (2024). DailyMed: Propranolol hydrochloride extended-release capsule labels.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
6. U.S. Food and Drug Administration. (2024). Paragraph IV drug product patent certifications and litigation information.
7. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.